End-of-day quote
Taipei Exchange
06:00:00 2024-04-25 pm EDT
|
5-day change
|
1st Jan Change
|
13.25
TWD
|
-1.12%
|
|
0.00%
|
-13.11%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
491.4
|
709.1
|
647.1
|
1,911
|
1,429
|
544.7
|
Enterprise Value (EV)
1 |
369.9
|
644.8
|
624.4
|
1,803
|
1,439
|
453.5
|
P/E ratio
|
-9.79
x
|
-13.1
x
|
-23
x
|
-24.6
x
|
-40.9
x
|
-5.01
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
0.99
x
|
1
x
|
1.18
x
|
4.77
x
|
3.25
x
|
1.95
x
|
EV / Revenue
|
0.75
x
|
0.9
x
|
1.13
x
|
4.5
x
|
3.27
x
|
1.62
x
|
EV / EBITDA
|
-9.69
x
|
-18.2
x
|
-21.5
x
|
-21
x
|
-228
x
|
-7.08
x
|
EV / FCF
|
187
x
|
-22.2
x
|
-10.1
x
|
-16.1
x
|
-12.1
x
|
8.14
x
|
FCF Yield
|
0.53%
|
-4.51%
|
-9.91%
|
-6.22%
|
-8.28%
|
12.3%
|
Price to Book
|
1.85
x
|
3.39
x
|
3.6
x
|
5.77
x
|
4.51
x
|
2.55
x
|
Nbr of stocks (in thousands)
|
24,326
|
24,326
|
24,326
|
35,720
|
35,720
|
35,720
|
Reference price
2 |
20.20
|
29.15
|
26.60
|
53.50
|
40.00
|
15.25
|
Announcement Date
|
4/1/19
|
3/30/20
|
3/30/21
|
3/25/22
|
3/31/23
|
3/13/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
495.6
|
712.6
|
550.2
|
400.7
|
439.6
|
279.3
|
EBITDA
1 |
-38.18
|
-35.49
|
-29.02
|
-85.7
|
-6.31
|
-64.08
|
EBIT
1 |
-51.29
|
-45.46
|
-34.91
|
-100.7
|
-36.07
|
-104.9
|
Operating Margin
|
-10.35%
|
-6.38%
|
-6.34%
|
-25.14%
|
-8.21%
|
-37.54%
|
Earnings before Tax (EBT)
1 |
-42.44
|
-53.15
|
-29.61
|
-86.32
|
-42.69
|
-124.6
|
Net income
1 |
-43.83
|
-54.14
|
-28.14
|
-68.87
|
-34.94
|
-108.8
|
Net margin
|
-8.84%
|
-7.6%
|
-5.11%
|
-17.19%
|
-7.95%
|
-38.96%
|
EPS
2 |
-2.064
|
-2.226
|
-1.157
|
-2.178
|
-0.9782
|
-3.047
|
Free Cash Flow
1 |
1.978
|
-29.05
|
-61.9
|
-112.1
|
-119.1
|
55.69
|
FCF margin
|
0.4%
|
-4.08%
|
-11.25%
|
-27.97%
|
-27.11%
|
19.94%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/1/19
|
3/30/20
|
3/30/21
|
3/25/22
|
3/31/23
|
3/13/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
10.6
|
-
|
Net Cash position
1 |
121
|
64.3
|
22.7
|
108
|
-
|
91.2
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-1.672
x
|
-
|
Free Cash Flow
1 |
1.98
|
-29.1
|
-61.9
|
-112
|
-119
|
55.7
|
ROE (net income / shareholders' equity)
|
-18.7%
|
-20.7%
|
-12.4%
|
-26.2%
|
-10.7%
|
-41.8%
|
ROA (Net income/ Total Assets)
|
-8.56%
|
-5.57%
|
-3.99%
|
-10.5%
|
-2.96%
|
-9.85%
|
Assets
1 |
512.1
|
971.4
|
705.7
|
656.4
|
1,180
|
1,105
|
Book Value Per Share
2 |
10.90
|
8.590
|
7.380
|
9.280
|
8.880
|
5.970
|
Cash Flow per Share
2 |
7.470
|
5.830
|
6.120
|
5.560
|
5.500
|
3.350
|
Capex
1 |
4.16
|
12.1
|
113
|
187
|
97.3
|
7.78
|
Capex / Sales
|
0.84%
|
1.69%
|
20.51%
|
46.6%
|
22.13%
|
2.79%
|
Announcement Date
|
4/1/19
|
3/30/20
|
3/30/21
|
3/25/22
|
3/31/23
|
3/13/24
|
|
1st Jan change
|
Capi.
|
---|
| -13.11% | 14.51M | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|